DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]

NCT03329690 PHASE2 COMPLETED Results posted

The primary purpose of this trial is to compare the efficacy and safety of DS-8201a and physician's choice treatment in HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma patients who have progressed on two prior treatment regimens including fluoropyrimidine agent, platinum agent, and trastuzumab.

Details

Lead sponsor	Daiichi Sankyo Co., Ltd.
Phase	PHASE2
Status	COMPLETED
Enrolment	233
Start date	Thu Nov 02 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Dec 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Neoplasm, Gastrointestinal

Interventions

• DS-8201a
• Physician's Choice

Countries

Japan, South Korea